Core Insights - Bausch Health reported third quarter consolidated revenues of $2.68 billion, reflecting a 7% increase on a reported basis and a 5% increase on an organic basis compared to the prior year [1] - The company achieved a GAAP net income attributable to Bausch Health of $179 million and a total GAAP net income of $181 million [1] - Consolidated adjusted EBITDA attributable to Bausch Health was $986 million, which includes an $81 million charge for acquired in-process research and development (IPR&D), marking an 8% increase on a reported basis year-over-year [1] - Excluding Bausch + Lomb, Bausch Health delivered its tenth consecutive quarter of year-over-year revenue and adjusted EBITDA growth, with reported revenue growth of 7% and adjusted EBITDA growth of 7% [1] - The company raised its full-year 2025 guidance for revenue, adjusted EBITDA, and adjusted cash flow from operations [1] - Bausch Health completed the acquisition of DURECT Corporation, enhancing its hepatology portfolio with the addition of Larsucosterol, a novel epigenetic modulator designated as a Breakthrough Therapy by the FDA for the treatment of alcohol-associated hepatitis [1]